<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Neurology/psychiatric</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Fed Circuit hands headache patent win back to Teva</title>
      <description>
        <![CDATA[Ever since Teva Pharmaceutical Industries Ltd. sued Eli Lilly and Co. several years ago, claiming Lilly’s migraine drug, Emgality (galcanezumab), infringed its headache treatment patents, the two companies have been on a litigation rollercoaster.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730484</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730484-fed-circuit-hands-headache-patent-win-back-to-teva</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Ajovy.webp?t=1776804181" type="image/jpeg" medium="image" fileSize="478143">
        <media:title type="plain">Ajovy</media:title>
        <media:description type="plain">Credit: Business Wire</media:description>
      </media:content>
    </item>
    <item>
      <title>Tortugas launches with $106M for neurology, neuropsychiatric drugs</title>
      <description>
        <![CDATA[Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730482</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730482-tortugas-launches-with-106m-for-neurology-neuropsychiatric-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Jeff-Jonas-CEO-and-Al-Robichaud-president-head-of-RD-Tortugas-4-21.webp?t=1776806199" type="image/jpeg" medium="image" fileSize="420579">
        <media:title type="plain">Jeff Jonas, CEO and Al Robichaud, president, head of R&amp;D, Tortugas Neuroscience</media:title>
        <media:description type="plain">Tortugas Neuroscience Inc. is led by Jeff Jonas, CEO (left), 
and Al Robichaud, president and head of R&amp;amp;D.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Entos and L-CMD Research Foundation collaborate</title>
      <description>
        <![CDATA[Entos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation with the aim of developing a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730541</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730541-entos-and-l-cmd-research-foundation-collaborate</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collaboration-illustration.webp?t=1600375790" type="image/png" medium="image" fileSize="669559">
        <media:title type="plain">Deal illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>XPC-837 restores network dysfunction in Dravet syndrome models</title>
      <description>
        <![CDATA[Researchers from Xenon Pharmaceuticals Inc. described the preclinical efficacy of XPC-837 in models of Dravet syndrome, a severe developmental and epileptic encephalopathy most commonly caused by de novo loss of function mutations in the <em>SCN1A</em> gene.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730539</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730539-xpc-837-restores-network-dysfunction-in-dravet-syndrome-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA.webp?t=1616096016" type="image/png" medium="image" fileSize="453052">
        <media:title type="plain">Brain and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>ASO targeting SNCA p.A53T shows promise in Parkinson’s</title>
      <description>
        <![CDATA[Vanda Pharmaceuticals Inc. presented data this week at the annual American Academy of Neurology conference regarding allele-specific antisense oligonucleotides (ASOs) that specifically target the mutant p.A53T allele from the <em>SNCA</em> gene while preserving the expression of the wild-type allele. The mutant allele is associated with increased risk of early-onset Parkinson’s disease (PD) and current ASOs target SNCA regardless of its mutation status.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730537</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730537-aso-targeting-snca-pa53t-shows-promise-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinsons-disease.webp?t=1589296424" type="image/png" medium="image" fileSize="449161">
        <media:title type="plain">Steadying hand while reaching for glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Aiming to Jimi the regulatory lock in psychedelics</title>
      <description>
        <![CDATA[The quest by psychedelic drugs for full legitimacy in the pharmaceutical world has seen marked progress as well as (fewer) setbacks of late, and developers are hopeful that an important corner has been turned.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730466</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730466-aiming-to-jimi-the-regulatory-lock-in-psychedelics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Psychedelic-pills.webp?t=1652215818" type="image/png" medium="image" fileSize="256746">
        <media:title type="plain">Pills shaded in psychedelic colors</media:title>
      </media:content>
    </item>
    <item>
      <title>Psychedelic space expanding on Trump’s EO</title>
      <description>
        <![CDATA[Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a surge in investment in companies researching and developing psychedelic drugs to treat mental health issues. The EO, Accelerating medical treatments for serious mental illness, is intended to address the increasing burden of suicide and serious mental illness, which impacts more than 14 million Americans.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730465</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730465-psychedelic-space-expanding-on-trumps-eo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Green-arrow-on-blue-abstract-background.webp?t=1776721603" type="image/jpeg" medium="image" fileSize="992857">
        <media:title type="plain">Green arrow on blue abstract background</media:title>
      </media:content>
    </item>
    <item>
      <title>Sichuan University discloses new diterpenoid alkaloid glycoside derivatives</title>
      <description>
        <![CDATA[Sichuan University has prepared and tested new diterpenoid alkaloid glycoside derivatives potentially useful for the treatment of pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730528</guid>
      <pubDate>Mon, 20 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730528-sichuan-university-discloses-new-diterpenoid-alkaloid-glycoside-derivatives</link>
    </item>
    <item>
      <title>Researchers synthesize PS derivatives for Alzheimer’s</title>
      <description>
        <![CDATA[Chinese researchers have published data regarding phosphatidylserine (PS) derivatives acting as neuroprotective compounds for Alzheimer’s disease (AD) therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730518</guid>
      <pubDate>Mon, 20 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730518-researchers-synthesize-ps-derivatives-for-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Digital-brain-and-silhouette.webp?t=1692736287" type="image/jpeg" medium="image" fileSize="186512">
        <media:title type="plain">Digital brain and silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>CRISPR and XIST silence one chromosome 21 copy in Down syndrome</title>
      <description>
        <![CDATA[A modified version of CRISPR-Cas9 has enabled, for the first time, the efficient integration of a large transgene capable of inactivating entire chromosomes into one of the three copies of chromosome 21 in Down syndrome-derived cells. The goal is to silence the extra copy to limit the gene-dosage imbalance that drives many features of trisomy 21. Researchers at Beth Israel Deaconess Medical Center turned to XIST, the long noncoding RNA responsible for the natural silencing of the X chromosome in females. Using this strategy, they achieved integration efficiencies of 20% to 40% and a partial reduction in the overexpression of chromosome 21 genes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730512</guid>
      <pubDate>Mon, 20 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730512-crispr-and-xist-silence-one-chromosome-21-copy-in-down-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/chromasomes-trisomy-21-karyotype.webp?t=1776698265" type="image/jpeg" medium="image" fileSize="303250">
        <media:title type="plain">Illustration of trisomy 21 karyotype</media:title>
      </media:content>
    </item>
    <item>
      <title>Dual inhibition of AChE and BChE shows neuroprotection in AD models</title>
      <description>
        <![CDATA[Researchers from the Government College University Faisalabad reported the discovery and preclinical characterization of IMS-48, a benzimidazole analogue designed to inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730452</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730452-dual-inhibition-of-ache-and-bche-shows-neuroprotection-in-ad-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/neurology-brain-protect.webp?t=1589299362" type="image/png" medium="image" fileSize="795113">
        <media:title type="plain">Hands holding brain</media:title>
      </media:content>
    </item>
    <item>
      <title>Sex differences shape gene activity across the human brain</title>
      <description>
        <![CDATA[Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions and cell types. Scientists at the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) used single-cell sequencing and unveiled distinct gene expression patterns regulated by hormones and sex chromosomes. This detailed map of the brain’s molecular biology shows how women and men switch on and off more than 3,000 brain genes differently and expands the catalogue of X chromosome genes that escape inactivation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730447</guid>
      <pubDate>Fri, 17 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730447-sex-differences-shape-gene-activity-across-the-human-brain</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-and-DNA2.webp?t=1663611764" type="image/png" medium="image" fileSize="254381">
        <media:title type="plain">Brain and DNA </media:title>
      </media:content>
    </item>
    <item>
      <title>Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’</title>
      <description>
        <![CDATA[The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically significant results do not read across to clinical benefit for patients with Alzheimer’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730393</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730393-meta-analysis-anti-amyloid-alzheimers-drugs-not-clinically-meaningful</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-brain-puzzle-alzheimers-parkinsons.webp?t=1745263787" type="image/jpeg" medium="image" fileSize="303211">
        <media:title type="plain">Elderly woman holding illustration of brain with missing puzzle piece</media:title>
      </media:content>
    </item>
    <item>
      <title>New GABA(B) receptor PAMs revealed in Addex Pharma patents</title>
      <description>
        <![CDATA[Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary incontinence, neuropathic pain, postoperative pain, neurological and psychiatric disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730441</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730441-new-gabab-receptor-pams-revealed-in-addex-pharma-patents</link>
    </item>
    <item>
      <title>FDA clears IND for Naturecell’s Astrostem-AU for autism</title>
      <description>
        <![CDATA[Naturecell Co. Ltd.’s U.S. subsidiary, Naturecell America, has received IND clearance from the FDA for Astrostem-AU, an autologous adipose-derived mesenchymal stem cell therapy for adults with autism spectrum disorder (ASD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730431</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730431-fda-clears-ind-for-naturecells-astrostem-au-for-autism</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-clay-model.webp?t=1583439267" type="image/png" medium="image" fileSize="219558">
        <media:title type="plain">Brain clay model</media:title>
      </media:content>
    </item>
    <item>
      <title>Biohaven reports details on discovery of BHV-2100</title>
      <description>
        <![CDATA[Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of rodents and humans. Its activation triggers acute pain, making drugs that target TRPM3 a potential approach to alleviate pain. Biohaven Ltd.’s BHV-2100 is the only selective TRPM3 antagonist in clinical development. The company recently disclosed the work leading to its discovery and early development, as well as the chemical structure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730377</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730377-biohaven-reports-details-on-discovery-of-bhv-2100</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Neurology-neuropathic-nerve-pain.webp?t=1691077523" type="image/jpeg" medium="image" fileSize="160260">
        <media:title type="plain">Man holding raised arm with illustrated overlay of nerves</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell announces Chinese clinical trial clearance for SST-001</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. has announced that SST-001 (18F-FD4), an α-synuclein-targeted PET tracer developed by Mabwell’s incubated company Synusight Biotech, has received clinical trial clearance from China’s National Medical Products Administration (NMPA). The planned phase I trial will enroll healthy volunteers, patients with multiple system atrophy (MSA), and patients with Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730374</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730374-mabwell-announces-chinese-clinical-trial-clearance-for-sst-001</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Radiopharmaceutical-illustration.webp?t=1680558525" type="image/png" medium="image" fileSize="129994">
        <media:title type="plain">Radiopharmaceutical illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal </title>
      <description>
        <![CDATA[Abbvie Inc. is buying exclusive rights to develop, manufacture and commercialize two Nav1.8 inhibitors for pain – HSK-55718 and HSK-51155 – from Haisco Pharmaceutical Group Co. Ltd. for $30 million up front and up to $715 million in milestone payments, plus royalties.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730297</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730297-abbvie-nabs-two-nav18-pain-projects-from-haisco-in-745m-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Pain-med-illustration2.webp?t=1776187647" type="image/jpeg" medium="image" fileSize="427247">
        <media:title type="plain">Open capsule delivering pain relief to body</media:title>
      </media:content>
    </item>
    <item>
      <title>Researchers unveil REDD1 as target for major depression</title>
      <description>
        <![CDATA[Investigators have shown that REED1 expression was elevated during stress, which in turn suppressed hippocampal synaptogenesis and induced major depressive disorder (MDD)-like behavior through mTORC1 signaling. The impact of REDD1 modulation was investigated in the preclinical setting for MDD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730350</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730350-researchers-unveil-redd1-as-target-for-major-depression</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Depression-illustration1.webp?t=1667507237" type="image/png" medium="image" fileSize="213888">
        <media:title type="plain">Man sitting on bed holding head</media:title>
      </media:content>
    </item>
    <item>
      <title>Investment to advance Quiver’s ASO for Dup15q syndrome</title>
      <description>
        <![CDATA[Quiver Bioscience Inc. has received a strategic investment from the Porta family office (Argentina) to advance the company’s antisense oligonucleotide (ASO) therapeutic program for chromosome 15q duplication (Dup15q) syndrome. The investment will fund preclinical activities, including safety studies for candidate selection as the program advances toward clinical development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730349</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730349-investment-to-advance-quivers-aso-for-dup15q-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-DNA.webp?t=1728053898" type="image/jpeg" medium="image" fileSize="371570">
        <media:title type="plain">Illustration of human brain and dna</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel caspase-2 inhibitor shows in vivo neuroprotective effects</title>
      <description>
        <![CDATA[Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). This fragment accumulates at synapses, disrupts glutamatergic signaling and contributes to cognitive impairment in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730346</guid>
      <pubDate>Tue, 14 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730346-novel-caspase-2-inhibitor-shows-in-vivo-neuroprotective-effects</link>
    </item>
    <item>
      <title>Abbvie licenses ex-China rights to Haisco pain compounds</title>
      <description>
        <![CDATA[Haisco Pharmaceutical Group Co. Ltd. has entered into an exclusive licensing agreement with Abbvie Inc., granting Abbvie the exclusive rights to develop, manufacture and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong and Macau.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730326</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730326-abbvie-licenses-ex-china-rights-to-haisco-pain-compounds</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-nerve-cell-pain.webp?t=1682600134" type="image/jpeg" medium="image" fileSize="413083">
        <media:title type="plain">3D illustration of a nerve cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Realta secures another $40M for its hypoxic ischemic encephalopathy treatment</title>
      <description>
        <![CDATA[Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the total the company has raised to more than $150 million through mission-driven investors and a family-office model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730228</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730228-realta-secures-another-40m-for-its-hypoxic-ischemic-encephalopathy-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/newborn-baby-infant.webp?t=1720795419" type="image/jpeg" medium="image" fileSize="169571">
        <media:title type="plain">Photo of hands holding a baby </media:title>
      </media:content>
    </item>
    <item>
      <title>PMP22-RNAi gives long-lasting protection in Charcot-Marie-Tooth</title>
      <description>
        <![CDATA[Researchers from the Cyprus Institute of Neurology and Genetics and collaborators report the development of a gene silencing therapy for <span style=" font-style: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; widows: 2; word-spacing: 0px; display: inline !important; float: none;">Charcot-Marie-Tooth type 1A</span>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730260</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730260-pmp22-rnai-gives-long-lasting-protection-in-charcot-marie-tooth</link>
    </item>
    <item>
      <title>MSD discloses new HCN1/2 blockers</title>
      <description>
        <![CDATA[Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and HCN2 blockers potentially useful for the treatment of pain, tinnitus, neurological and mood disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730252</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730252-msd-discloses-new-hcn1-2-blockers</link>
    </item>
    <item>
      <title>Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics</title>
      <description>
        <![CDATA[Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy. The underlying technology of sonogenetics provides the ability to manipulate cellular activity via ultrasound-sensitive ion channels that respond to acoustic pressure. These channels may be endogenous, or could be delivered by targeted vectors to specific cell types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730256</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730256-sononeu-wins-52m-arpa-h-grant-for-ultrasound-activated-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Foot-neuropathy-illustration.webp?t=1775587782" type="image/jpeg" medium="image" fileSize="740144">
        <media:title type="plain">Neuropathy illustrated in legs and feet</media:title>
      </media:content>
    </item>
    <item>
      <title>MMP inhibitors divulged in Accure Therapeutics patent</title>
      <description>
        <![CDATA[Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as potentially useful for the treatment of epilepsy, schizophrenia, autism, cancer, mood disorder, sepsis, Alzheimer’s disease and vascular disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730200</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730200-mmp-inhibitors-divulged-in-accure-therapeutics-patent</link>
    </item>
    <item>
      <title>Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics</title>
      <description>
        <![CDATA[Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730136</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730136-sononeu-wins-52m-arpa-h-grant-for-ultrasound-activated-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Foot-neuropathy-illustration.webp?t=1775587782" type="image/jpeg" medium="image" fileSize="740144">
        <media:title type="plain">Neuropathy illustrated in legs and feet</media:title>
      </media:content>
    </item>
    <item>
      <title>Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent</title>
      <description>
        <![CDATA[Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson's disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730176</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730176-orexin-ox2-receptor-agonists-disclosed-in-vertex-pharmaceuticals-patent</link>
    </item>
    <item>
      <title>Acadia Pharmaceuticals presents GPR88 agonists</title>
      <description>
        <![CDATA[Acadia Pharmaceuticals Inc. has reported new G protein-coupled receptor GPR88 agonists that are potentially useful for the treatment of tardive dyskinesia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730175</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730175-acadia-pharmaceuticals-presents-gpr88-agonists</link>
    </item>
  </channel>
</rss>
